Latest Oncology News

FDA Approval Sought for Poziotinib in HER2 Exon 20–Mutated NSCLC

FDA Approval Sought for Poziotinib in HER2 Exon 20–Mutated NSCLC

December 6th 2021

Kristi Rosa

A new drug application seeking the approval of poziotinib as a potential therapeutic option for patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations has been submitted to the FDA.

MRD-Guided Treatment Represents the Future in CLL

MRD-Guided Treatment Represents the Future in CLL

December 6th 2021

Maggie Tibbitt

Minimal-residual disease has become an important prognostic factor in guiding treatment decisions for patients with chronic lymphocytic leukemia.

Secura Bio Withdraws Duvelisib Relapsed/Refractory Follicular Lymphoma Indication in the United States

Secura Bio Withdraws Duvelisib Relapsed/Refractory Follicular Lymphoma Indication in the United States

December 6th 2021

Kristi Rosa

Secura Bio, Inc. has decided to voluntarily withdraw the indication of duvelisib for use in patients with relapsed or refractory follicular lymphoma following at least 2 previous systemic therapies.

Breast Reconstruction Specialist Dr. Andrea Moreira Joins AHN from Cleveland Clinic

Breast Reconstruction Specialist Dr. Andrea Moreira Joins AHN from Cleveland Clinic

December 6th 2021

Andrea Moreira, MD, a board-certified plastic surgeon specializing in the use of advanced techniques in breast reconstruction, has joined Allegheny Health Network from Cleveland Clinic and will serve as Co-Director of the Microsurgery and Breast Reconstruction Program in the AHN Division of Plastic Surgery.

Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple Myeloma

Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple Myeloma

December 6th 2021

Shambavi Richard, MD

Various immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.

Latest Oncology Videos

All Oncology News

Dr. Till on Data With Liso-Cel Vs Other Products Under Examination in MCL

April 14th 2021

Brian Till, MD

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.

Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers

April 13th 2021

Vivek Subbiah, MD

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.

Neoadjuvant Cemiplimab Elicits Complete Pathological Responses in HCC

April 13th 2021

Courtney Marabella

Significant tumor necrosis was observed in 20% of patients with resectable hepatocellular carcinoma who received neoadjuvant treatment with cemiplimab-rwlc.

FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer

April 13th 2021

Kristi Rosa

The FDA has granted an accelerated approval to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.

Trastuzumab Deruxtecan Benefit/Risk Profile in Advanced Cancer Supported by Pooled Analysis

April 13th 2021

Hayley Virgil

The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.

Dr. del Rio on Remaining Questions With the COVID-19 Vaccines

April 13th 2021

Carlos del Rio, MD

Carlos del Rio, MD, discusses remaining questions with the COVID-19 vaccines.

Dr. Vij on the Potential of CELMoDs in Relapsed/Refractory Multiple Myeloma

April 13th 2021

Ravi Vij, MD, MBA

Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.

Dr. Coveler on the Toxicity Profile of NUC-3373 in Metastatic CRC

April 13th 2021

Andrew Coveler, MD

Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.

Atezolizumab Induces Durable Activity Irrespective of MSI Status in Advanced Solid Tumors With TMB ≥16 Mut/Mb

April 13th 2021

Audrey Sternberg

Atezolizumab elicited durable clinical activity irrespective of microsatellite instability status in patients with advanced solid tumors with a tumor mutational burden of more than 16 mutations per megabase.

Tailoring Targeted Therapies in Metastatic CRC

April 13th 2021

Hayley Virgil

Syed Kazmi, MD, highlights the go-to regimens for patients with mCRC.

AFM13 Showcases 100% ORR in Relapsed/Refractory CD30+ Hodgkin Lymphoma

April 13th 2021

Gina Mauro

AFM13, an innate cell engager, demonstrated an objective response rate of 100% in adult patients with CD30-positive, relapsed/refractory Hodgkin lymphoma.

Multi-Omics Approach to Personalized Therapy Shows Feasibility in Metastatic Breast Cancer

April 13th 2021

Audrey Sternberg

A multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data has demonstrated feasibility in patients metastatic breast cancer vs DNA sequencing alone.

Telisotuzumab Vedotin Demonstrates Efficacy and Tolerability in Previously Treated c-MET+ NSCLC

April 13th 2021

Sara Karlovitch

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer.

Diagnosis of Acute and Chronic GVHD

April 13th 2021

Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Hematologist-oncologists review the typical presentation and diagnosis of acute and chronic GVHD and define how severity is classified.

Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations

April 13th 2021

Jason Broderick

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

See All News